SLC5A2 and diabetic kidney disease: Neuen et al.’s (2019) meta-analysis supports the argument for SGLT2i as crucial tools in slowing the progression of DKD and was reinforced by pooled data from several trials, which showed that SGLT2 lower albuminuria and halt the decline in estimated glomerular filtration rate (eGFR) [52].